First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05304962
• Other study ID #: RGT-419B_01-101
• Status: Recruiting
• Phase: Phase 1
• Start date: March 4, 2022
• Est. completion date: August 28, 2024

Study information

• Verified date: October 2023
• Source: Regor Pharmaceuticals Inc.
• Contact: Regor Central Office
• Phone: 617-315-9070
• Email: rgt-419b_01-101[@]regor.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: August 28, 2024
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female >/= 18 years old

2. ECOG Performance Status 0 to 1

3. HR+, HER2- tumor by most recent biopsy with measurable disease

4. Have had no more than 1 prior line of cytotoxic chemotherapy in the ABC setting AND no serious/severe toxicity to a prior CKD4/6i AND no known contraindication to receiving RT-419B AND have had all acute/residual toxic effects of any prior therapy

5. In the ABC setting, eligible subjects must have failed to respond to or progressed after <3 lines of prior CDK4/6i therapy and unlimited lines of prior HT and have had no more than 1 prior line of chemotherapy. Eligible subjects must have received and progressed on any combination of HTs including any approved AI, SERD, or SERM, and/or any approved CDK4/6i in any order.

(5a) For subjects in Arm B, at least one line of prior therapy must have included a locally approved HT which was well tolerated and which the subject is willing to receive again (5b) Subjects with tumors harboring a PIK3CA mutation will be allowed to enroll, and treatment with a PI3Ki in combination with HT will be allowed as a prior line of therapy. Surgical excision of tumor tissue accompanied by chemotherapy or targeted therapy is also counted as 1 line of prior treatment.

Exclusion Criteria:

1. Presence of visceral metastases with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and/or rapid progression of disease

2. Pregnant or planning to become pregnant

3. Prior irradiation to >25% of the bone marrow and/or inadequate bone marrow function or evidence of clinically significant end-organ damage

4. Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14 days prior to Cycle 1, Day 1

5. Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol

6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• RGT-419B
oral capsules
• RGT-419B in combination with hormonal therapy
RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)

Locations

Country	Name	City	State
United States	Hem-Onc Associates of the Treasure Coast	Port Saint Lucie	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Regor Pharmaceuticals Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Symptom Burden	Change from baseline in symptom burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) from baseline to end of treatment	through study completion, an average of 1 year
Primary	Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in singlet and doublet therapy	Number of subjects who have a confirmed DLT at each cohort dose level in singlet and doublet study arms during the first 28-day cycle of RGT-419B treatment.	4 weeks (1 cycle)
Secondary	Safety & Tolerability - Incidence, Severity, and Causality of all Treatment Emergent Adverse Events (TEAEs)	Incidence, severity, and causality of all TEAEs will be assessed for all patient participating from Day 1 dosing through end of study.	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cmax	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-Time Curve (AUC0-t)	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-Time Curve to Infinity (AUC0-inf)	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Plasma Decay Half-Life (t 1/2)	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Time to Reach Maximum Observed Plasma Concentration (Tmax)	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Accumulation rate after multiple doses	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cumulative urinary excretion	Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification	through study completion, an average of 1 year
Secondary	Tumor Response assessed by Investigator according to RECIST v1.1	Tumor response measured by radiologic imaging techniques at baseline and throughout the study	through study completion, an average of 1 year
Secondary	QTc Interval - Changes in corrected QT interval	Number of subjects with a clinically significant increase from baseline in corrected QT (QTc) interval on repeated ECGs during RGT-419B monotherapy.	through study completion, an average of 1 year